CML HealthCare Inc.'s Subsidiary, Hemostasis Reference Laboratory Awarded Contract Extension with Isis Pharmaceuticals

CML HealthCare Inc. (TSX:CLC) (the "Company" or "CML"), a leading
community-based provider of laboratory and medical imaging services in Ontario
and British Columbia, today announced that its subsidiary, Hemostasis Reference
Laboratory Inc. ("HRL") has been awarded a contract extension to work with Isis
Pharmaceuticals ("Isis") on their Factor XI ("ISIS-FXIRX") Phase II clinical
trial. ISIS-FXIRX is an antisense drug designed to treat clotting disorders. HRL
is currently the coagulation testing laboratory of choice for ISIS-FXIRX Phase I
clinical trial.


Under the new contract, HRL will be the specialty coagulation laboratory testing
all ISIS-FXIRX Phase II clinical trial samples. HRL has worked closely with Isis
in the past to develop specific testing panels that would best suit their needs,
including reagent sensitivities for FXI, as well as numerous Thrombin Generation
assays.


"We are excited to continue strengthening our partnership with ISIS, a leading
antisense drug discovery and development company. HRL's technical proficiencies
in developing customized testing panels will provide ISIS with the ideal
platform to further their clinical trials," said Thomas Wellner, President and
Chief Executive Officer of CML. "We look forward to continuing to service
contract research organizations, pharmaceutical and biotechnology companies with
our in-depth capabilities and unique service offerings."


About CML HealthCare Inc.

Based in Mississauga, Ontario, CML HealthCare Inc. a leading community-based,
medical diagnostic services provider in Canada operating 114 Client C.A.R.E.
Centres in Ontario, 84 imaging centres in Ontario and British Columbia, and its
subsidiary, Hemostasis Reference Laboratory, a reference laboratory in Ontario
focused on specialized coagulation testing and equipment calibration for
international customers. CML is publicly-traded on the Toronto Stock Exchange
under the symbol "CLC" and has approximately 89.8 million common shares
outstanding. For more information, please visit www.cmlhealthcare.com or follow
CML on Twitter @cmlhealthcare.


About ISIS-FXIRx

ISIS-FXIRx is an antisense drug discovered and being developed by Isis
Pharmaceuticals. ISIS-FXIRx is designed to treat clotting disorders by
inhibiting the production of Factor XI, a clotting factor produced in the liver
that is an important component of the coagulation pathway. High levels of Factor
XI increase the risk of thrombosis, a process involving aberrant blood clot
formation responsible for most heart attacks and strokes. Elevated levels of
Factor XI also increase the risk of venous thrombosis, a common problem after
surgery, particularly major orthopedic procedures, such as knee or hip
replacement. People who are deficient in Factor XI have a lower incidence of
thromboembolic events with minimal increase in bleeding risk.


FOR FURTHER INFORMATION PLEASE CONTACT: 
CML HealthCare Inc.
Alice Dunning, MBA, CFA
Director, Corporate Communications
[e-mail]
www.cmlhealthcare.com